Trials / Unknown
UnknownNCT04979390
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1316 | SHR-1316 administrated intravenously (IV) at protocol defined dose levels |
Timeline
- Start date
- 2021-08-10
- Primary completion
- 2022-02-10
- Completion
- 2022-07-31
- First posted
- 2021-07-28
- Last updated
- 2021-07-28
Source: ClinicalTrials.gov record NCT04979390. Inclusion in this directory is not an endorsement.